贝派地酸中间体 | 738606-44-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 贝派地酸中间体
• 英文名称: 8-isocyano-2,2,14,14-tetramethyl-8-(toluene-4-sulfonyl)-pentadecanedioic acid diethyl ester
• 英文别名: Diethyl 8-isocyano-2,2,14,14-tetramethyl-8-tosylpentadecanedioate；diethyl 8-isocyano-2,2,14,14-tetramethyl-8-(4-methylphenyl)sulfonylpentadecanedioate
• CAS: 738606-44-5
• 化学式: C₃₁H₄₉NO₆S
• 分子量: 563.799
• InChiKey: UZZLDIFAUXUEAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  39
• 可旋转键数：
  20
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  99.5
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  贝派地酸中间体 在 盐酸 、 水 作用下， 生成 2,2,14,14-四甲基-8-氧代-十五烷二酸二乙酯
  参考文献：
  名称：

  一种抗高血酯药物中间体的制备方法

  摘要：

  本发明公开了一种抗高血酯药物中间体的制备方法，包括a使2,2‑二甲基‑7‑氯庚酸乙酯和对甲基苯磺酰甲基异氰在含乙醇钠的极性非质子溶剂中反应后，用去离子水淬灭反应溶液，并用不溶于水的极性溶剂萃取分液，获得的有机相为中间体I；b酸解中间体I后，利用碱中和反应溶液并分液，将有机相浓缩至干，获得中间体II；c将中间体II溶解于乙醇中，并利用碱水溶液水解中间体II后，酸化反应溶液并萃取分液，将有机相浓缩，并加入正庚烷结晶后，过滤，获得的滤饼为抗高血酯药物中间体8‑氧代‑2,2,14,14‑四甲基十五烷二酸。本发明能够降低制备抗高血酯药物中间体8‑氧代‑2,2,14,14‑四甲基十五烷二酸的难度，提高制备效率。

  公开号：

  CN116589341A
• 作为产物：
  描述：

  7-溴-2,2-二甲基庚酸乙酯 在 对甲基苯磺酰甲基异腈 、 四丁基碘化铵 、 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 20.0h， 生成 贝派地酸中间体
  参考文献：
  名称：

  [EN] HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  [FR] COMPOSES HYDROXYLES ET COMPOSITIONS DE REGULATION DU CHOLESTEROL ET UTILISATIONS ASSOCIEES

  摘要：

  公开号：

  WO2004067489A3

文献信息

• Hydroxyl compounds and compositions for cholesterol management and related uses
  申请人：Dasseux Henri Jean-Louis

  公开号：US20050043278A1

  公开（公告）日：2005-02-24

  The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型羟基化合物、包含羟基化合物的组合物以及用于治疗和预防多种疾病和病症的方法，例如但不限于衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、脂质代谢异常、高血压、阳痿、炎症、胰岛素抵抗、胆汁中脂质清除、肥胖、胆汁中氧化固醇清除、胰腺炎、帕金森病、过氧化物酶体增殖激活受体相关疾病、胆汁中磷脂清除、肾脏疾病、败血症、代谢综合征（例如X综合征）、血栓性疾病等。本发明的化合物和方法还可以用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法与其他治疗剂（例如降胆固醇和降血糖药物）的联合治疗中有用。
• HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：Dasseux Henri Jean-Louis

  公开号：US20070179120A1

  公开（公告）日：2007-08-02

  The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型羟基化合物、包含羟基化合物的组合物以及用于治疗和预防各种疾病和病症的方法，例如但不限于衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢障碍、脂质代谢异常、高血压、阳痿、炎症、胰岛素抵抗、胆汁中脂质的排泄、肥胖症、胆汁中氧化固醇的排泄、胰腺炎、帕金森病、过氧化物酶体增殖物激活受体相关疾病、胆汁中磷脂的排泄、肾脏疾病、败血症、代谢综合征（例如X综合征）、血栓性疾病。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗药物（例如降胆固醇和降血糖药物）联合使用。
• 一种贝派地酸中间体的制备方法
  申请人：武汉武药科技有限公司

  公开号：CN115504914A

  公开（公告）日：2022-12-23

  本发明公开了一种贝派地酸中间体的制备方法，其中涉及贝派地酸中间体：8‑异氰基‑2,2,14,14‑四甲基‑8‑甲苯磺酰基十五烷二酸二酯、2,2,14,14‑四甲基‑8‑氧代十五烷二酸二酯的制备方法，其无需使用氢化钠，有效保障制备过程安全；无需添加四丁基碘化铵(TBAI)等相转移催化剂，有效降低了制备成本；各中间体的收率高，纯度高，无需繁琐复杂、成本较高的后处理过程，例如柱层析，利于工业化生产。
• 一种贝派地酸中间体的合成方法
  申请人：武汉武药科技有限公司

  公开号：CN117551009A

  公开（公告）日：2024-02-13

  本发明公开了一种贝派地酸中间体的合成方法，反应式如下：#imgabs0#其中，R选自：烷基、环烷基、芳基、芳烷基；X为卤素；所述制备方法包括如下步骤：式Ⅰ所示化合物与式Ⅱ所示化合物在第一微通道反应器中反应得到式Ⅲ化合物。本发明提供的贝派地酸中间体的制备方法，反应时间短，碱用量少，收率高，纯度高；无需使用NaH，安全；无需添加TBAI等相转移催化剂，有效降低了制备成本，环境友好；无需繁琐复杂、成本较高的后处理过程，例如柱层析，利于工业化生产。
• Long Hydrocarbon Chain Keto Diols and Diacids that Favorably Alter Lipid Disorders in Vivo
  作者：Ralf Mueller、Jing Yang、Caiming Duan、Emil Pop、Otto J. Geoffroy、Lian Hao Zhang、Tian-Bao Huang、Sergey Denisenko、Bruce H. McCosar、Daniela C. Oniciu、Charles L. Bisgaier、Michael E. Pape、Catherine Delaney Freiman、Brian Goetz、Clay T. Cramer、Krista L. Hopson、Jean-Louis H. Dasseux

  DOI：10.1021/jm040006p

  日期：2004.11.1

  Keto-substituted hydrocarbons with 11 - 19 methylene and bis-terminal hydroxyl and carboxyl groups have been synthesized and evaluated in both in vivo and in vitro assays for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats [Crl:(ZUC)-faBRI following 1 and 2 weeks of oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ketone functionality and the gem dimethyl or methyl/aryl substituents. Furthermore, biological activity was found to be greatest in both in vivo and in vitro assays for the tetramethyl-substituted keto diacids and diols (e.g., 10c, 10g, 14c), and the least active were shown to be the bis(arylmethyl) derivatives (e.g., 10e, 10f, 14f). Compound 14c dose-dependently elevated HDL-cholesterol, reduced triglycerides, and reduced NEFA, with a minimum effective dose of 30 mg/kg/day. Compound 10g dose-dependently modified non-HDL-cholesterol, triglycerides, and nonesterified fatty acids, with a minimum effective dose of 10 mg/kg/day. At this dose, compound 10g elevated HDL-cholesterol levels 2-3 times higher than pretreatment levels, and a dose-dependent reduction of fasting insulin and glucose levels was observed.